Skip to main content
Premium Trial:

Request an Annual Quote

The Whole Picture

The recent clearance of Illumina's MiSeqDx by the US Food and Drug Administration has gotten clinicians and researchers excited, writes Melissa Healy at the Los Angeles Times.

In November, FDA cleared Illumina's MiSeqDx system as well as three related assays. The company plans to market the platform for about $125,000, Healy notes.

Having such a machine in the clinic, she says, will enable physicians to order a test to look at patients' genomes wholesale rather than going through it gene by gene with targeted tests. "Why would you study just a few genes when you can see the whole thing?" Stanford University's Michael Snyder tells her.

Healy adds, though, that communicating what all this new information means to patients is a challenge. "We know that people get state-of-the-art genetic counseling and still walk out of that office confused," Harvard Medical School's Robert Green says.

Still, the clearance of the Illumina platform may pave the way for other systems. "We certainly hope to see more [platforms like MiSeqDx]," FDA's Elizabeth Mansfield tells Healy. "Bring it on."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.